Navigation Links
MAP Pharmaceuticals Reports Second Quarter of 2011 Financial Results
Date:8/4/2011

$3.5 million and $37.7 million of which was recognized, respectively, as collaboration revenue for the three and six months ended June 30, 2011. The remaining $22.3 million is deferred revenue and will be amortized as collaboration revenue over the estimated obligation periods.

Research and development (R&D) expenses for the three and six months ended June 30, 2011 were $7.3 million and $18.8 million, respectively, compared to $8.2 million and $18.0 million, respectively, for the same periods in 2010. For the three months ended June 30, 2011 compared to the same period in 2010, the decrease in R&D expenses was due primarily to a decrease in clinical and other project expenses to support the LEVADEX Phase 3 clinical program, partially offset by an increase in personnel related expenses including stock-based compensation. For the six months ended June 30, 2011 compared to the same period in 2010, the increase in R&D expenses was due primarily to an increase in personnel related expenses including stock-based compensation, partially offset by a decrease in other expenses.  

Sales, general and administrative (SG&A) expenses for the three and six months ended June 30, 2011 were $4.8 million and $9.6 million, respectively, compared to $3.9 million and $7.8 million, respectively, for the same periods in 2010. For the three and six months ended June 30, 2011 compared to the same periods in 2010, the increase in SG&A expenses was due primarily to an increase in personnel related expenses including stock-based compensation, and an increase in professional services expenses.

For the three and six months ended June 30, 2011, non-cash stock-based compensation and depreciation expense were approximately $2.0 million and $4.4 million, respectively.

About MAP PharmaceuticalsMAP Pharmaceuticals is an emerging biopharmaceutical company focused on developing and commercializing new therapies to address undermet patient needs
'/>"/>

SOURCE MAP Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. Vanda Pharmaceuticals Reports Second Quarter 2011 Results
2. Savient Pharmaceuticals Reports Second Quarter 2011 Financial Results
3. Christian S. Schade to Join Omthera Pharmaceuticals as Executive Vice President and Chief Financial Officer
4. Cadence Pharmaceuticals Reports Second Quarter 2011 Financial Results
5. Onyx Pharmaceuticals Reports Second Quarter 2011 Financial Results
6. Access Pharmaceuticals Adds Blue Cross Blue Shield of Hawaii, SummaCare and AvMed to MuGard Payer List
7. Lyophilisation for Pharmaceuticals: Technology and Services Market 2011-2021 - What are the Revenue Prospects?
8. Cadence Pharmaceuticals to Present at Two Investment Conferences During the Month of August 2011
9. Avanir Pharmaceuticals to Present at Two Investor Conferences in August
10. Pacira Pharmaceuticals, Inc. Announces Data Presentations at the 38th Annual Meeting & Exposition of the Controlled Release Society
11. MAP Pharmaceuticals Announces FDA Acceptance for Filing of NDA for LEVADEX®
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/19/2014)... Ky. , Dec. 18, 2014 Baptist Health ... States to receive full Atrial Fibrillation with Electrophysiology ... Care (SCPC). Atrial fibrillation is the most common ... that in some cases can lead to stroke and possible ... United States have atrial fibrillation and the numbers ...
(Date:12/19/2014)... , Dec. 18, 2014   Aratana ... a biopharmaceutical company focused on the licensing, development ... today announced positive results from its pivotal field ... for treating pain in dogs with osteoarthritis.  In ... pain assessment scores that were statistically significant compared ...
(Date:12/19/2014)... separating membrane market has witnessed robust development with the ... as a later starter. In 2012, the size of ... billion, with the proportion worldwide soaring to 16.3%. It is ... will continue its growth rate by around 20% in the ... to roughly RMB25 billion. An integrated membrane industrial ...
Breaking Medicine Technology:Baptist Health Lexington First in the Nation to Receive Atrial Fibrillation with EPS Accreditation 2Baptist Health Lexington First in the Nation to Receive Atrial Fibrillation with EPS Accreditation 3Aratana Therapeutics Announces Positive Top-Line Results from AT-001 Pivotal Field Study in Client-Owned Dogs with Osteoarthritis 2Aratana Therapeutics Announces Positive Top-Line Results from AT-001 Pivotal Field Study in Client-Owned Dogs with Osteoarthritis 3Aratana Therapeutics Announces Positive Top-Line Results from AT-001 Pivotal Field Study in Client-Owned Dogs with Osteoarthritis 4Aratana Therapeutics Announces Positive Top-Line Results from AT-001 Pivotal Field Study in Client-Owned Dogs with Osteoarthritis 5Separation Membranes Market (Company, Country & Application) Research Reports for Global and Chinese Regions 2Separation Membranes Market (Company, Country & Application) Research Reports for Global and Chinese Regions 3
... and PARIS, Feb. 24, 2011 /PRNewswire-Asia-FirstCall/ -- Sanofi-aventis (EURONEXT: ... it has completed the previously announced acquisition of BMP ... stockholders held today, BMP Sunstone stockholders approved the adoption ... Star 2010, Inc., a wholly owned subsidiary of sanofi-aventis, ...
... Conn., Feb. 24, 2011 Mira Dx announced today that ... acceptance of a pivotal breast cancer study in the January ... BRCA1 coding sequence mutations are associated with breast ... less than 5% of breast cancer risk. The research identified ...
Cached Medicine Technology:Sanofi-Aventis Announces Approval and Closing of BMP Sunstone Acquisition Creating a Strong Consumer Health Care Platform in China 2Mira Dx Licenses Triple Negative Breast Cancer Risk Variant from Yale University 2
(Date:12/17/2014)... A group of 127 scientists sent an ... reaction to a recent statement by the center that was ... derogated the efficacy of all brain exercises. , Signatories to ... of the center’s statement critical of brain exercise companies that ... overstated its case, in a document it had entitled “A ...
(Date:12/17/2014)... FL (PRWEB) December 17, 2014 No ... not been able to eradicate the head louse parasite—a ... hassle for parents. Each year between six and twelve ... Troopers, the Miami-based lice removal treatment company comes to ... non-toxic and environmentally friendly. With its track record of ...
(Date:12/17/2014)... Project Veritas is releasing a video interview of ... and Obamacare architect Jonathan Gruber to public attention. Award-winning ... which is being distributed on YouTube. , During the ... the Affordable Care Act in order to hide a ... per year tax grab. , “President Obama promised us ...
(Date:12/17/2014)... Mozes HealthDay Reporter , TUESDAY, ... infectious diseases, one worrisome phenomenon is when an illness that ... -- known as zoonosis -- is not uncommon and keeps ... an animal-borne disease might make inroads into the human population. ... -- and the culprits in this case were guinea pigs. ...
(Date:12/17/2014)... News) -- Poor students get more fruits and vegetables at ... But, the opposite is true for students from wealthier ... at school may give a healthy boost to poor students, ... the family income level, students all ate a similar amount ... The study was published recently in the journal Preventive ...
Breaking Medicine News(10 mins):Health News:Scientists to Stanford: Research Shows Brain Exercises Can Work 2Health News:Scientists to Stanford: Research Shows Brain Exercises Can Work 3Health News:Scientists to Stanford: Research Shows Brain Exercises Can Work 4Health News:Lice Troopers Announces New Lice Treatment Clinic in Coral Gables to Service Key Biscayne, Coconut Grove, Kendall, Brickell & South Miami 2Health News:Project Veritas: James O’Keefe Interviews the Man Who Discovered Jonathan Gruber Videos 2Health News:Guinea Pigs Can Be Source of Serious Strep Infection 2Health News:Guinea Pigs Can Be Source of Serious Strep Infection 3Health News:Poor Students Eat Healthier Foods at School, Study Finds 2
... , , NASHVILLE, Tenn., ... and payment cycle management solutions for the healthcare industry, ... implemented the Emdeon Patient Responsibility Estimator(SM) solution. Emdeon Patient ... BroMenn,s patient access staff to inform patients of their ...
... , , PISCATAWAY, ... Board: MLSS), the recognized leader in advanced injection technologies, ... Office has issued a Notice of Allowance for Milestone,s ... disposable hand piece for fluid administration. Milestone,s proprietary, ...
... , , WACO, Texas, Aug. 24 ... out a universal health care plan in their new book ... published by Cambridge University Press, that does not create a ... coverage or health care of Americans who currently have coverage. ...
... , BERKELEY HEIGHTS, N.J., Aug. 24 Authentidate ... of secure Health Information Exchange and workflow management services, today ... of home healthcare services and medical equipment, selected Authentidate,s Inscrybe(TM) ... physicians. , , "We believe that Inscrybe ...
... Boost Your Local Blood Supply , , ... its regional operations in Manhattan, Long Island, Hudson Valley, Brooklyn / ... blood now through Labor Day to help ensure that your community ... NYBC also asks that people who have donated blood once in ...
... , , ... Inc., announced today that it has received European CE Mark ... System. The device is now approved for use in improving ... disease. , , The novel vProtect(TM) Luminal ...
Cached Medicine News:Health News:Emdeon and BroMenn Healthcare System Take the Lead on Consumer Price Transparency 2Health News:Emdeon and BroMenn Healthcare System Take the Lead on Consumer Price Transparency 3Health News:Emdeon and BroMenn Healthcare System Take the Lead on Consumer Price Transparency 4Health News:Milestone Scientific Announces Notice of Allowance From US Patent and Trademark Office 2Health News:Milestone Scientific Announces Notice of Allowance From US Patent and Trademark Office 3Health News:Baylor University Economists Call for Different Tack on Health Care Insurance 2Health News:LifeCare Solutions Simplifies Healthcare Order Process Management with Authentidate's Inscrybe Healthcare 2Health News:LifeCare Solutions Simplifies Healthcare Order Process Management with Authentidate's Inscrybe Healthcare 3Health News:LifeCare Solutions Simplifies Healthcare Order Process Management with Authentidate's Inscrybe Healthcare 4Health News:Give Blood Today for Community Preparedness 2Health News:Give Blood Today for Community Preparedness 3Health News:vProtect Luminal Shield (TM) from Prescient Medical Receives CE Mark 2
... Chemstrip Micral test strips are an ... in urine samples. When the test ... sample, urine passes via a wick ... albumin present in the sample binds ...
The A350 test is used for POC testing in hospital emergency departments, replacing the need to draw blood for alcohol testing. Each hash mark is 0.02% or 20 mg/dL....
AccuSign DOA Series tests include tests for Amphetamines, Barbituates, Benzodiazepines, Cocaine, Methadone, Methamphetamines, Nicotine (Cotinine), Opiates, Phencyclidine, THC, Tricyclic Antidepressan...
... drugs of abuse tests are highly accurate in ... recommended cut-off as confirmed by GC/MS testing. This ... specific alternative method (such as GC/MS) must be ... Professional judgment should be applied to any drug ...
Medicine Products: